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Selection of single antigen-specific B cells to identify their expressed antibodies is of 
considerable interest for evaluating human immune responses. Here, we present a 
method to identify single antibody-expressing cells using antigen-conjugated fluorescent 
beads. To establish this, we selected Folate Receptor alpha (FRα) as a model antigen 
and a mouse B cell line, expressing both the soluble and the membrane-bound forms 
of a human/mouse chimeric antibody (MOv18 IgG1) specific for FRα, as test antibody- 
expressing cells. Beads were conjugated to FRα using streptavidin/avidin-biotin bridges 
and used to select single cells expressing the membrane-bound form of anti-FRα. Bead-
bound cells were single cell-sorted and processed for single cell RNA retrotranscription 
and PCR to isolate antibody heavy and light chain variable regions. Variable regions 
were then cloned and expressed as human IgG1/k antibodies. Like the original clone, 
engineered antibodies from single cells recognized native FRα. To evaluate whether 
antigen-coated beads could identify specific antibody-expressing cells in mixed immune 
cell populations, human peripheral blood mononuclear cells (PBMCs) were spiked with 
test antibody-expressing cells. Antigen-specific cells could comprise up to 75% of cells 
selected with antigen-conjugated beads when the frequency of the antigen-positive 
cells was 1:100 or higher. In PBMC pools, beads conjugated to recombinant antigens 
FRα and HER2 bound antigen-specific anti-FRα MOv18 and anti-HER2 Trastuzumab 
antibody-expressing cells, respectively. From melanoma patient-derived B cells selected 
with melanoma cell line-derived protein-coated fluorescent beads, we generated a 
monoclonal antibody that recognized melanoma antigen-coated beads. This approach 
may be further developed to facilitate analysis of B cells and their antibody profiles at the 
single cell level and to help unravel humoral immune repertoires.
Keywords: B cell, humoral immune response, single cell sorting, fluorescent bead, human antibodies, antibody 
expression, antigen
2Correa et al. Antibody-Expressing Cells Identified with Antigen-Coated Beads
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 493
releVance TO The research TOPic: 
single cell aPPrOaches TO sTUDY 
The iMMUne sYsTeM
The selection and study of single antigen-specific B cells and the 
identification of their expressed antibodies can help shed light 
on the nature and functions of the human humoral immune 
response. In our study, we present an antigen-conjugated fluore-
scent bead methodology designed to identify and isolate single 
antibody-expressing cells and to derive and clone matched heavy 
and light chain antibody variable regions into full length antibod-
ies. We believe that our single cell-to-functional antibody strategy 
falls within the scope of this research topic, as it opens the way 
for opportunities to analyze B  cells and their antibody profiles 
at the single cell level and may be potentially applied to help 
unravel diverse humoral immune repertoires in different health 
and disease states.
inTrODUcTiOn
The study of humoral immunity may be key to understand 
human health, aging, and disease, as well as to predict or moni-
tor host immune responses to pathogen challenge and disease 
progression (1). Moreover, dissecting B cell responses could help 
inform medical interventions such as preventative vaccines or 
therapeutic treatments (2, 3). Currently, therapeutic monoclonal 
antibodies are part of the standard care of treatment for various 
conditions including diabetes, autoimmune and allergic diseases, 
and various types of cancer. A big proportion of these antibodies 
are fully mouse or mouse–human chimeras (4). Therefore, iden-
tification of fully human, heavy (H), and light (L) variable region-
matched antibodies may be of interest for clinical applications, as 
administration of fully human antibodies is considered less likely 
to induce antidrug antibody responses compared with chimeric 
or humanized antibodies (5). Immune monitoring of human 
B  cells recognizing specific antigens, alongside identification, 
cloning, and production of their cognate monoclonal antibodies, 
may, therefore, be of substantial value to help evaluate reactivity 
and immunological response to these antigens.
Analyses of the antibody repertoires of B  cells have been 
reported in the human setting and in animal models, with the 
most common applications in the study of autoimmune diseases 
(6), viral infections, and B cell malignancies (7–9). Some stud-
ies have employed high-throughput sequencing of heavy chain 
variable regions or of paired H and L variable region sequences 
(10, 11). Ultra-high-throughput sequencing techniques have 
also been developed, capable of analyzing repertoires of thou-
sands of B cells from small human blood samples, with some 
allowing the mapping of paired H and L variable regions, in a 
few hours (12–14).
B cells may also be a source of antigen-specific antibodies for 
clinical diagnostics or for therapeutic applications. Existing meth-
ods to identify antigen-specific B cells and generate monoclonal 
antibodies include ex vivo B cell culture approaches, which could 
promote the survival and expansion of certain B  cell subsets, 
screening of the culture supernatants to identify B cell reactiv-
ity and fluorescent-activated cell sorting (15–20). An essential 
element in the process of selecting antigen-specific B  cells is 
detection of antibodies with a certain degree of specificity. This 
could be achieved by screening cell culture supernatants through 
ELISPOT assays or ELISA-based methods using immobilized 
recombinant antigens or cells (16, 20). Screening cell culture 
supernatants by ELISA, although highly sensitive, represents only 
a surrogate parameter and antigen reactivity should ultimately be 
confirmed only after sequencing and expression of the selected 
clone. For all these applications, the gold standard of identifying 
antigen-specific antibodies remains the expression of the recom-
binant antibody and further evaluation of its antigen recognition 
properties. Workflows to facilitate selection of single human 
B cells without ex vivo growth, stimulation, and clone expansion, 
and which do not require sampling of cell culture supernatants 
could offer additional tools for the study of human B cell immu-
nity. Novel approaches to address these requirements involve the 
use of modified fluorescent tetramers for direct B cell screening 
by fluorescent-activated cell sorting (21, 22).
In this study, we describe the design of a bead-based meth-
odology to identify single antibody-expressing B cells, and to 
clone and produce antigen-specific antibodies. The workflow 
features bead-based identification and isolation of specific 
B cells using direct fluorescent-activated cell sorting, sequenc-
ing, and cloning of matched heavy and light chain variable 
regions in a single full sequence antibody expression vector 
system, and expression and testing the antigenic reactivity of 
the antibody clone. The workflow is designed to avoid ex vivo 
B cell expansion and secondary clone selection and to facilitate 
antibody generation and downstream evaluation.
MaTerials anD MeThODs
human samples
Human immune cells were isolated from venous blood of healthy 
volunteers and patients with malignant melanoma. Specimens 
were collected with informed written consent in accordance 
with the Declaration of Helsinki. The study was conducted at 
King’s College London, King’s College London, Guy’s and St 
Thomas’ NHS Foundation Trust (08/H0804/139 approved by 
London Bridge NRES committee; 16/LO/0366 approved by 
London-Central NRES Committee). Human peripheral blood 
mononuclear cells (PBMC) were isolated from 40  ml blood 
using Ficoll® Paque Plus density centrifugation (GE Healthcare).
cell culture
Cell culture was performed using aseptic technique at 37°C in 
a humidified atmosphere in 5% CO2, unless otherwise speci-
fied. The human ovarian carcinoma cell line IGROV1 naturally 
over-expressing folate receptor alpha (FRα) was grown in RPMI 
1640 GlutaMAX™ medium (Thermo Scientific) supplemented 
with 10% fetal calf serum (FCS). The human breast cancer cell 
line MDA-MB-231 was grown in DMEM GlutaMAX™ medium 
(Thermo Scientific) supplemented with 10% FCS. The perma-
nently transfected murine myeloma cell lines SP2/0-MOv18 
specific for FRα and SP2/0-SF25, recognizing a colon carcinoma 
antigen (23), were cultured in Dulbecco’s Modified Eagle’s 
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Medium plus 10% FCS as previously described (24). The human 
embryonic kidney cell lines, Expi293F cells, were cultured in 
serum-free Expi293 expression medium (Thermo Scientific) on 
a Stuart orbital shaker at 125 rpm at 8% CO2.
Transient expression of human 
Monoclonal antibodies in expi293F cells
Expi293F cells were transfected with pVitro1-hygro-mcs antibody 
constructs using the ExpiFectamine293 Transfection kit (Thermo 
Scientific) as per manufacturer’s instructions. The anti-human 
epidermal growth factor receptor 2 (HER2) and the melanoma-
associated antigen-specific chondroitin sulfate proteoglycan 
(CSPG4) antibody constructs were previously described (25, 26).
Fluorescent Beads
Different avidin- or streptavidin-coated fluorescent beads of differ-
ent sizes were used (Table S1 in Supplementary Material): XMAP 
LumAvidin Microspheres (LumAvidin 5.6 µm) (L100-L150-01) 
with a size of 5.6 µm and fluorescent in the APC channel (from 
Luminex); Sphero Coated-fluorescent particles (Spherotec Inc.) 
as follows: Sphero Streptavidin-coated fluorescent particles, Nile 
Red 0.4–0.6 µm (SA-Red 0.5 µm) (Cat No SVFP-0556-5), Sphero 
Avidin-coated fluorescent particles Nile Red, 0.7–0.9 µm (A-Red 
0.8 µm) (Cat No VFP-0856-5), and Sphero Streptavidin-Coated 
fluorescent particles, Blue, 1.0–1.9 µm (SA-Blue 1.1 µm) (Cat No 
SVFP-1068-5).
generation of Melanoma cell line  
Protein extracts
To biotinylate proteins of melanoma cell lines, confluent cell 
monolayers were washed with PBS and borate buffer pH 9. 
Then, sulfo-NHS-LC-biotin at 1  mg/ml in PBS was added 
and incubated for 20  min on ice. The reaction was quenched 
with 200  mM Tris, 120  mM NaCl pH 7.4, and the cells were 
subsequently extensively washed with PBS. Cell lysis buffer 
(Cell Signaling Technology) containing 0.1% Triton and supple-
mented with 2 mM PMSF was added to the monolayer and the 
cells were harvested by scrapping. Lysates were briefly sonicated 
and incubated on an orbital rocker for 30 min at 4 C. The lysates 
were cleared by centrifugation at 900 × g for 15 min, followed by 
a second centrifugation at 12,000 × g for 30 min. Supernatants 
were either used immediately or stored at −80°C.
coupling of recombinant Proteins  
to Fluorescent Beads
Recombinant Folate Receptor α (FRα) (R&D Systems, Cat 
no 5646-FR) and human epidermal growth factor receptor 2 
(ErbB2/HER2) Fc chimera (R&D Systems, Cat no 1129-ER) 
were reconstituted in PBS at 0.1  mg/ml as recommended by 
the manufacturer. Biotins with three different arms were used: 
(i) sulfo-NHS-LC-biotin with a spacer arm of 22.4 Å; (ii) sulfo-
NHS-LC-LC-biotin with a spacer arm of 30.5 Å, and (iii) NHS-
PEG12-biotin with a spacer arm of 56 Å (all from Pierce-Thermo 
Fisher Scientific). The three forms of biotin were reconstituted 
following the manufacturer’s instructions and mixed with the 
recombinant proteins in PBS at a 20:1 (biotin:recombinant 
protein) molar ratio and incubated for 90 min at room tempera-
ture (RT). Free biotin was removed by dialysis in PBS.
For binding of biotin-conjugated FRα to LumAvidin 5.6 µm 
microspheres, 100 µl of microsphere solution was washed with 1 ml 
of 1% BSA–PBS–0.05% sodium azide, spun at 8,000 × g for 2 min, 
and pellets were resuspended in 100  µl of 1% BSA–PBS–0.05% 
sodium azide. Then, 37.5  µg of biotin-conjugated recombinant 
protein (in 300 µl of PBS-1% BSA) was added to the beads and 
mixed, by rotation, for up to 16 h at RT. Beads were then washed 
three times with 1 ml of 1% BSA–PBS–0.05% sodium azide and 
resuspended in 100 µl of 1% BSA–PBS–0.05% sodium azide.
For binding of biotin-conjugated FRα to all Sphero fluo-
rescent particles, 100 µl of beads were washed with 1 ml of 1% 
BSA–PBS–0.05% sodium azide, spun at 13,000 ×  g for 20  min 
at RT, and the pellet was resuspended in the original volume of 
beads with 1% BSA–PBS–0.05% sodium azide. Then, 25  µg of 
biotin-conjugated recombinant protein was added and mixed, 
by rotation, for 2–16 h at RT. After binding, beads were washed 
three times with 1  ml 1% BSA–PBS–0.05% sodium azide and 
resuspended in 100 µl of 1% BSA–PBS–0.05% sodium azide.
For binding of biotin-conjugated cell extracts to LumAvidin 
5.6  µm microspheres, 200  µl of microsphere solution were 
washed with 1  ml of 1% BSA–PBS–0.05% sodium azide, spun 
at 8,000 × g for 2 min, and pellets were resuspended in 200 µl 
of 1% BSA–PBS–0.05% sodium azide. Then, 300  µl of biotin-
conjugated cell extracts were added to the beads and mixed, by 
rotation, for up to 16 h at RT. After binding, beads were washed 
three times with 1 ml of 1% BSA–PBS–0.05% sodium azide and 
resuspended in 200 µl of 1% BSA–PBS–0.05% sodium azide. For 
each test, 15 µl beads were used.
Fluorescent labeling of conjugated Beads
To check that FRα/HER2 proteins were attached on the bead sur-
face, conjugated beads were stained with specific antibodies for 
FRα/HER2. Conjugated beads (10 µl) were incubated in 200 µl 
of FACS buffer (5% FCS–PBS) for 20 min at RT, then, 1 µg of the 
monoclonal antibody MOv18 (anti-FRα), anti-HER2 [previously 
described in Ref. (27)] or isotype control antibodies were added. 
In all described experiments, the hapten-specific in-house pro-
duced monoclonal antibody anti-NIP IgG was used as an isotype 
control. The beads were incubated for 30 min at 4°C, washed with 
2 ml of FACS buffer, and incubated with anti-human immuno-
globulin (Ig) antibody conjugated to FITC (Vector Laboratories) 
for another 30 min at 4°C. After a final wash with FACS buffer, 
stained beads were analyzed on a FACSCanto™ flow cytometer 
(BD Biosciences). Beads coated with melanoma cell line extracts 
were tested by staining with a monoclonal IgG antibody recogniz-
ing the melanoma-associated antigen CSPG4.
Binding of conjugated Beads to cells 
expressing MOv18 or anti-her2 
antibodies
Sp2/0 B cells transfected with MOv18 IgG1 antibody or Expi293F 
cells transfected to transiently express anti-HER2 antibodies 
(105 cells in 100 µl of FACS buffer) were incubated with 2–30 µl 
of conjugated beads for 30–45 min at RT, washed with 2 ml of 
TaBle 1 | Nested PCR immunoglobulin primers.
Primer 
name
sequence 5′ → 3′ amplified 
fragment
VH1L CCATGGACTGGACCTGGA Heavy chain
VH2L CAGATGGACATACTTTGTTCCAC Heavy chain
VH3L CCATGGAGTTTGGGCTGAGC Heavy chain
VH4L CGATGAAACACCTGTGGTTCTT Heavy chain
VH5L ATGGGGTCAACCGCCATCCT Heavy chain
VH6L GATGTCTGTCTCCTTCCTCAT Heavy chain
VH1F CAGGTGCAGCTGGTGCAGTCTG Heavy chain
VH2F GTCTTGTCCCAGGTCAACTTAAGGGAGTCTT Heavy chain
VH3F GAGGTGCAGCTGGTGGAGTCTG Heavy chain
VH4F CAGGTGCAGCTGCAGGAGTCGG Heavy chain
VH5F GAGGTGCAGCTGCTGCAGTCTG Heavy chain
VH6F CTGTCACAGGTACAGCTGCAGCAGTCAG Heavy chain
IGREV CCAACTCTCTTGTCCACCTTGG Heavy chain
L-Vk1/2 ATGAGGGTCCCCGCTCAGCTGCTGG Kappa light chain
L-Vk3 CTCTTCCTCCTGCTACTCTGGCTCCCAG Kappa light chain
L-Vk4 ATTTCTCTGTTGCTCTGGATCTCTG Kappa light chain
Ck 543-566 GTTTCTCGTAGTCTGCTTTGCTCA Kappa light chain
Pan-Vk ATGACCCAGACTCCATCCACCCTG Kappa light chain
Ck 494-516 GTGCTGTCCTTGCTGTCCTGCT Kappa light chain
L-Vλ1 GGTCCTGGGCCCAGTCTGTGCTG Lambda light chain
L-Vλ12 GGTCCTGGGCCCAGTCTGCCCTG Lambda light chain
L-Vλ3 GCTCTGTGACCTCCTATGAGCTG Lambda light chain
L-Vλ4/5 GGTCTCTCTCGCAGCCTGTGCTG Lambda light chain
L-Vλ6 GTTCTTGGGCCAATTTTATGCTG Lambda light chain
L-Vλ7 GGTCCAATTCCCAGGCTGTGGTG Lambda light chain
L-Vλ8 GAGTGGATTCTCAGACTGTGGTG Lambda light chain
Cλ-1 CACCAGTGTGGCCTTGTTGGCTTG Lambda light chain
F-Vλ1 CAGTCTGTGTTGACGCAGCC Lambda light chain
F-Vλ2 CAGTCTGCCCTGACTCAGCC Lambda light chain
F-Vλa3 TCTTATGAGCTGACACAGCCA Lambda light chain
F-Vλa3l TCTTCTGAGCTGACTCAGGACCC Lambda light chain
F-Vλ4ab GAGCTTGTGCTGACTCAATC Lambda light chain
F-Vλ4c CTGCCTGTGCTGACTCAGC Lambda light chain
F-Vλ5/9 CAGCCTGTGCTGACTCAGCC Lambda light chain
F-Vλa6 AATTTTATGCTGACTCAGCCCCACT Lambda light chain
F-Vλ7/8 CAGACTGTGGTGACCCAGGAG Lambda light chain
F-Vλa10 CAGGCAGGGCTGACTCAG Lambda light chain
Cλ-2 GGGTGGGAACAGAGTGACC Lambda light chain
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FACS buffer, and left on ice until analyzed on a FACSCanto™ 
flow cytometer (BD Biosciences).
spiking of PBMc with antibody-
expressing cells
Sp2/0 cells expressing MOv18 IgG or the control antibody SF25 
were prestained with anti-mouse MHC Class I-PE antibody to 
be used with Streptavidin SA-Blue 1.1 µm or LumAvidin 5.6 µm 
beads (Table S1 in Supplementary Material) or anti-mouse 
CD45 APC antibody (BD Biosciences)/Far-red cell tracking dye 
(Thermo Fisher Scientific) to be used with Avidin fluorescent 
A-Red 0.8 µm beads. Expi293F cells expressing anti-HER2 or the 
control anti-CSPG4 antibody (3–4 days post transfection) were 
labeled with Far-red cell tracking dye (Thermo Fisher Scientific). 
Beads coated with recombinant antigens were incubated with 
100 µl of blocking buffer (10% FCS–PBS, unless stated) for 30 min 
at RT. Then, 106 PBMCs were added in 100 µl of blocking buffer 
and spiking was conducted with pre-labeled Sp2/0-or Expi293F 
cells at different PBMC:pre-labeled cell ratios in another 50 µl. 
Cells and beads were incubated for 30 min at 4°C, washed with 
2 ml of FACS buffer, and stained with DAPI before samples were 
analyzed on a FACSCanto™ flow cytometer (BD Biosciences). 
The data were analyzed using the FlowJo® software version 10.4.1. 
The actual dilution was calculated by dividing the number of live 
Far-red positive events (antigen-specific cells) by the number of 
live Far-red negative events (PBMC).
cell sorting
Sp2/0 cells transfected with MOv18 IgG and stained with FRα-
conjugated fluorescent beads were sorted on 96-well plates at 1, 5, 
and 10 cells/well directly into 10 µl of lysis buffer (Single cell lysis 
kit, Ambion-Thermo Fisher Scientific), using an BD FACSAria™ 
II Cell Sorter (BD Biosciences) with an 85 µm nozzle. Samples 
were transferred to 0.2 ml PCR tubes and stored at −80°C until 
further processing. Enriched B cells were obtained from 40 ml 
peripheral blood of two patients with melanoma using RosetteSep 
human B cell enrichment cocktail (StemCell Technologies) fol-
lowing the manufacturer’s instructions. B  cells were incubated 
with Fc Blocking Reagent (Miltenyi Biotec) for 10 min at RT and 
stained with anti-CD19 FITC, anti-CD22 FITC, anti CD45 PE (all 
antibodies from BD Biosciences) and simultaneously incubated 
with 15 µl of 5.6 µm LumiAvidin beads coated with SK-MEL-28 
melanoma cell extracts for 30 min on ice in sort buffer (PBS, 2% 
BSA, 2 mM EDTA). Immediately before acquisition, DAPI live/
dead dye was added. The cells binding fluorescent beads were 
sorted into 72-well plates at 1 cell/well into 10 µl of lysis buffer as 
above. For B cells, a 70 µm nozzle was used.
ig Variable region cloning
PCR tubes containing sorted cells in lysis buffer were thawed and 
reverse transcription was performed in a thermal cycler using the 
SuperScript VILO cDNA Synthesis kit (Thermo Fis her Scientific) 
following the manufacturer’s recommendations. Variable regions 
of Ig heavy and light chains were amplified by two rounds of PCR 
amplification in 20 µl mix, using 10 µl of Phusion Flash polymer-
ase mix per reaction (Finnzymes), each primer at 0.5 µM, 2 µl 
of the reverse transcriptase reaction as template for the first 
PCR and 2 µl of the first PCR as template in the second PCR. 
For the variable regions in the MOv18 heavy chain, the cycles for 
amplification were: 1 min at 98°C, 36 cycles of 10 s at 98°C, 15 s at 
60°C, and 15 s at 72°C, followed by a final step at 72°C for 1 min. 
In the first PCR, the reverse primer was IgGRev in the constant 
region of the IgG, and in the second PCR, the reverse primer was 
MOv18VH_R. For the variable regions in the MOv18 light chain, 
the cycles for amplification were: 1 min at 98°C, 36 cycles of 10 s 
at 98°C, 15 s at 57°C, and 15 s at 72°C, followed by a final step at 
72°C for 1 min. In the first PCR, the reverse primer was Kappa_R 
in the constant region of the kappa chain, and in the second PCR, 
the reverse primer was MOv18K_R. Primers: MOv18VH_F: 
CAGGTTCAACTGCAGCAGTCTGGA; MOv18VH_R: TGA 
GGAGACGGTGACTGAGGTTCC; MOv18VK_F: GATATC 
CAGATGACACAGACTACA; MOv18VK_R: TTTCCAGCT 
TGGTGCCTCC; IgGRev: CCAACTCTCTTGTCCACCTTGG; 
Kappa_R: GTTTCTCGTAGTCTGCTTTGCTCA. Forward and 
reverse primers used for the amplification of unknown Ig light 
and heavy chain fragments (Table 1), and the nested PCR protocol 
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were previously described (28). PCR products were separated 
on agarose gels, purified using the QIAquick gel extraction kit 
(Qiagen), and cloned using the ZeroBlunt PCR cloning kit (Life 
Technologies). Six colonies were grown for each PCR band, plas-
mid DNA purified using QIAprep spin miniprep kit (Qiagen) and 
sequenced by Source Bioscience using the M13 forward primer. 
Sequences were analyzed using IMGT/V-QUEST (29).
recombinant antibody cloning and 
expression
Heavy and light chain variable regions were cloned in pVitro-
hygro-1 (Invivogen) using polymerase incomplete primer 
extension (PIPE) cloning as previously described (25). In brief, 
pVitro-hygro-1, containing pre-cloned human antibody heavy 
and light constant region cassettes (gamma 1/kappa) was used 
as a template in two separate PIPE PCR reactions to amplify two 
linear plasmid fragments with partially single-stranded 5″ ends. 
Similarly, the Ig heavy and light chain variable regions were PIPE 
PCR-amplified, using the pCR-Blunt constructs, generated previ-
ously, as PCR templates. Next, the PCR products were diluted four 
times with ddH2O and mixed in a ratio of 1:1:1:1, incubated at RT 
for 1 h, and 10 µl of the mixture were used to transform Top10 
OneShot™ E. coli cells (Thermo Fisher Scientific). Successful 
cloning was confirmed by Sanger sequencing (Source BioScience). 
MOv18 IgG1/k was expressed transiently in Expi293F™ cells 
(Thermo Fisher Scientific), as described in Ref. (26). Antibodies, 
secreted in the Expi293F™ culture supernatant, were purified 
using a Protein A column (Thermo Fisher Scientific) and stored 
in PBS at 4°C.
resUlTs
Workflow for identification of antibody-
expressing single cells Using antigen-
conjugated Fluorescent Beads
We designed a process to allow the identification of antigen-
specific antibody-expressing B  cells, which can be performed 
without prior ex vivo growth or secondary screening of B cells. 
To establish this system, we selected Folate Receptor alpha (FRα) as 
a model antigen. As the test antibody-expressing cells, we selected 
a B  cell line expressing both the soluble and the membrane-
bound [B cell receptor (BCR)] form of a human/mouse chimeric 
antibody (MOv18 IgG1 clone) specific for FRα. The workflow 
(Figure 1) entails coupling of fluorescent polystyrene beads with 
the nominal antigen, Folate Receptor alpha (FRα), followed by 
binding of FRα-coated beads to anti-FRα antibody-expressing 
B cells. Single bead-conjugated cells were identified and isolated 
by FACS sorting directly onto microplates containing lysis buffer. 
RNA released from single cells was converted to cDNA using 
reverse transcription followed by a semi-nested RT-PCR with Ig 
specific primers. Matched variable H and L chains were sequenced 
and cloned into a single expression vector containing the H and L 
constant IgG1 region sequences as previously reported (25, 26). 
The full antibody was then expressed in a human expression host. 
The antibody was purified and antibody specificity for the antigen 
was tested on target antigen-expressing cells.
antigen-coupled Fluorescent Bead 
recognition by Monoclonal antibodies 
and by specific antibody-expressing  
B cells
We first established the workflow using APC fluorochrome 
LumAvidin Microspheres of 5.6 µm diameter (LumAvidin 5.6 µm; 
Table S1 in Supplementary Material). Prior to interrogating 
the ability of these beads to bind antibody-expressing cells, we 
used flow cytometric evaluations to confirm that fluorescent 
beads could be successfully coupled to antigens. We tested the 
antigens FRα and HER2 conjugated to fluorescent beads. The 
anti-FRα antibody MOv18 IgG bound to FRα-conjugated beads, 
and the HER2-specific antibody trastuzumab bound to HER-2-
conjugated beads. On the other hand, the hapten-specific mono-
clonal antibody NIP IgG showed only background binding to 
FRα-conjugated or to HER-2-conjugated beads, and no binding 
was detected on beads incubated with secondary antibody alone 
(Figure 2A). We also interrogated different coupling agents with 
varying biotin lengths (LC-biotin, 22.4 Å; LC-LC-biotin, 30.5 Å; 
PEG12-biotin, 56 Å) to assess whether the distance between bead 
and antigen from the bead surface could affect antigen recogni-
tion by anti-FRα-expressing B  cells. We found no significant 
differences in MOv18 IgG antibody binding to bead-conjugated 
FRα with respect to any of these coupling agents (Figure 2B).
We then established a model system using microsphere- 
coupled FRα and anti-FRα antibody-expressing B cells. We con-
firmed that a small proportion of FRα+ LumAvidin 5.6 µm micro-
spheres recognized single anti-FRα antibody-expressing B  cells 
(Sp2/0-MOv18) (Figure  3A). When single bead-bound cells 
were isolated into lysis buffer-containing microplate wells by flow 
cytometric sorting, single cell PCR yielded matched H and L chain 
variable region DNA products were detected to be of the expected 
size (Figure 3B). Antibody variable region sequences were cloned 
into a pVITRO1 vector containing human IgG1/k constant 
region cassettes and the antibody was expressed in Expi293F™  
cells. Subsequently, the cloned IgG1 antibody was used to assess 
binding to IGROV1 cells, which express native cell surface human 
FRα. Flow cytometric evaluations confirmed that the anti-FRα 
antibody cloned from a sorted single antibody-expressing B cell 
was able to specifically recognize antigen-expressing IGROV1 cells. 
The cloned anti-FRα antibody did not recognize MDA-MB-231 
breast carcinoma cells that do not express FRα (Figure 3C).
These findings confirmed that it is possible to extract matched 
variable region sequences from single antibody-expressing cells 
selected by recognition of specific antigen-coated microspheres. 
Selection of single B  cells allowed the identification of the 
expected matched variable regions and permitted the cloning and 
production of the corresponding monoclonal antibody from a 
single cell. This antibody was able to recognize natively expressed 
cell surface FRα.
influence of Microsphere Diameter and 
Biotin length on specific recognition  
of antigen-expressing B cells
Since we observed that FRα+ microspheres were able to bind only 
a small proportion of single anti-FRα antibody-expressing B cells 
FigUre 1 | Workflow for identification of antigen-specific monoclonal antibodies derived from single cell cloning. Biotinylated antigen (Folate Receptor alpha, FRα) 
was conjugated to fluorescent beads conjugated to streptavidin or avidin. Antigen-coated beads could bind cells expressing an antigen-specific immunoglobulin  
(Ig) and bead-bound cells were purified using cell sorting. RNA from sorted cells was reverse transcribed and Ig variable regions were amplified by nested PCR, 
sequenced, and cloned using the dual expression plasmid pVITRO1 containing human heavy and light chain constant region cassettes (gamma1/kappa). Antibodies 
were expressed in a human cell expression system, purified, and tested for antigen binding.
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(Sp2/0-MOv18), we investigated whether microsphere diameter 
or the FRα-biotin on the beads could influence specific recogni-
tion of antibody-expressing cells.
We confirmed that Sp2/0-MOv18 IgG cells expressing MOv18 
IgG on the cell surface could be recognized by human recom binant 
FRα (Figure 4A). As observed with recombinant antibody bind-
ing to FRα-coated microspheres (Figure 2), the distance between 
bead and antigen from the bead surface did not affect antigen 
recognition by anti-FRα antibody-expressing Sp2/0-MOv18 
cells (Figure 4B). However, the proportion of the Sp2/0-MOv18 
cells recognized by fluorescent beads coated with FRα differed 
with bead size or type: microspheres of smaller bead diameters 
(SA-Red 0.5 µm and SA-Blue 1.1 µm) appeared to bind a higher 
proportion of B cells (70.3 and 54.9%, respectively) compared to 
the LumAvidin 5.6 µm beads (1.4%) (Figures 4C,D).
The length of the biotin arm had minor effects on the bind-
ing of the smaller sized (A-Red 0.8  µm and SA-Blue 1.1  µm) 
microspheres to Sp2/0-MOv18 cells. The PEG12-biotin arm 
showed a slightly higher proportion of microsphere-attached 
Sp2/0-MOv18 cells (69–71% of cells) compared with beads 
attached to FRα via LC-LC-biotin (59–61%) or LC-biotin 
(54–64%) arms (Figure  4E). Binding of FRα-coated fluores-
cent beads appeared to be specific for antibody-expressing 
B  cells, since FRα-coated beads bound 54–71% of Sp2/0-
MOv18 IgG cells, while FRα-coated beads bound 6–9% of 
Sp2/0 non-specific antibody-expressing cells used as controls 
(Figure 4E).
These findings suggest that bead size or type could influence 
the proportion of possible antibody-expressing B cells recognized 
by antigen-conjugated fluorescent beads.
FigUre 2 | Antigen-coated beads were recognized by specific antibodies. (a) Fluorescent microspheres (SA-Blue 1.1 µm) coated with human recombinant FRα 
(top) or HER2 (bottom) conjugated to LC-LC-biotin were incubated with no antibody, non-specific monoclonal anti-NIP (control), MOv18 (top right), or anti-HER2 
antibodies (bottom right). Bead-bound antibodies were detected using secondary goat anti-human FITC-conjugated antibodies. Gates indicate positive antibody 
staining above controls. (B) Recombinant FRα conjugated to biotin of different arm lengths was used to coat fluorescent LumAvidin 5.6 µm microspheres, and 
microspheres were stained with MOv18 IgG1 antibody. The percentage of MOv18 IgG1-bound beads and mean fluorescence intensity (MFI) values of positive 
populations are indicated in each dot plot.
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FigUre 3 | Binding of folate receptor α+ beads to B cells expressing MOv18 antibody. (a) Gating strategy for Sp2/0 cells (105 in 100 µl FACS buffer) expressing 
MOv18 IgG, incubated with fluorescent LumAvidin 5.6 µm microspheres coated with FRα via PEG12-biotin. Single live cells binding to the beads were sorted into 
individual wells in a 96-well plate. (B) Agarose electrophoresis of the heavy and light chain variable regions of immunoglobulin sequences obtained from the Sp2/0 
cells and amplified by PCR. (c) Flow cytometric evaluations of purified MOv18 antibody, produced in-house from single Sp2/0 cell Ig sequences, and expressed 
as a human/chimeric IgG1. MOv18 recognized FRα-overexpressing IGROV1 cancer cells but not FRα-negative MDA-MB-231 breast cancer cells. Dark gray 
histogram: unstained IGROV1 cells; light gray histogram: non-specific anti-NIP (monoclonal) antibody alone; Red histogram: MOv18 antibody cloned from  
a single B cell.
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evaluation of specific Detection of 
antibody-expressing B cells in PBMc 
samples by antigen-conjugated 
Fluorescent Beads
Since alongside specific binding of beads to antibody-expressing 
B  cells, we also detected non-specific binding of FRα-coated 
beads to control Sp2/0 cells (Figure 4E), we further investigated 
the background binding of fluorescent beads to freshly isolated 
human PBMCs. A proportion (~1%) of human PBMCs (top 
panel) and also of human B  cells (CD19+ cells, lower panel) 
could bind to FRα-coated beads in most likely a non-specific 
manner (Figure 5A). Different blocking agents did not appear 
to reduce the levels of background binding (Table S2 in 
Supplementary Material). Furthermore, A-Red 0.8 µm, SA-Blue 
1.1  µm, and LumAvidin 5.6  µm FRα-coupled (PEG12-biotin) 
beads were incubated with PBMCs and binding was directly 
compared to recognition of Sp2/0-MOv18 IgG cells (used as 
positive controls). FRα-coupled A-Red 0.8  µm microspheres 
showed 54.3% specific and 0.56% non-specific B cell recognition, 
while SA-Blue 1.1 µm microspheres showed 53.4% specific and 
1.36% non-specific recognition of B  cells. On the other hand, 
the larger sized LumAvidin 5.6 µm microspheres showed 8.7% 
specific and 0.07% non-specific binding (Figure 5B). This sug-
gested that the smaller diameter beads were more likely to select 
antibody-expressing cells.
FigUre 4 | Continued
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FigUre 5 | Background binding of fluorescent beads to human peripheral blood mononuclear cells (PBMC). (a) Flow cytometric analyses demonstrating the effects 
of blocking agents in reducing the background binding of the SA-Blue 1.1 µm and A-Red 0.8 µm beads to cells. Top panels: non-specific binding to total PBMC; 
Bottom panels: background among B cells. (B) Analyses of FRα-coated A-Red 0.8 µm, SA-Blue 1.1 µm, and LumAvidin 5.6 µm beads incubated with PBMCs (to 
establish the background staining of the beads), or with Sp2/0-MOv18 cells (to establish binding to antigen-reactive positive cells).
FigUre 4 | The size of the fluorescent beads conjugated to FRα affects binding of MOv18 IgG-expressing cells. (a) Sp2/0-MOv18 IgG cells stained with FRα-biotin 
confirm expression of MOv18 IgG on the cell surface. Gray histogram: unstained cells; Blue histogram: cells given Streptavidin_AF488 alone; Red histogram: cells 
stained with FRα-biotin and Streptavidin_AF488. (B) Flow cytometric analyses of the effects of the biotin arm lengths on fluorescent FRα-coated LumAvidin 5.6 µm 
bead binding to Sp2/0-MOv18 cells. (c) Sp2/0-MOv18 cell binding to FRα-coated LumAvidin 5.6 µm beads was confirmed with an anti-human IgG antibody. This 
showed binding of beads to the Sp2/0 cells expressing higher levels of anti- FRα antibody. (D) Flow cytometric analyses of the effects of fluorescent FRα-coated 
bead size (LumAvidin 5.6 µm, SA-Blue 1.1 µm, SA-Red 0.5 µm) on binding to Sp2/0-MOv18 cells. (e) Effects of length of the biotin arm on binding of A-Red 0.8 µm 
and SA-Blue 1.1 µm beads to Sp2/0-MOv18 cells (left panels: cells alone).
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In order to analyze whether, and at what frequency, anti-
FRα antibody-expressing B  cells in PBMC samples may be 
detected by FRα-coupled beads, we spiked human PBMC with 
Sp2/0-MOv18 cells at different frequencies and we detected 
double-positive (FRα+/Sp2/0+) events by flow cytometry 
(Figure  6A). FRα-coupled A-Red 0.8  µm fluorescent beads 
FigUre 6 | Detection of antibody-expressing B cells in peripheral blood mononuclear cells (PBMC) samples using fluorescent beads. (a) Schematic representation 
of Sp2/0 “spiking” of PBMCs. Flow cytometric dot plots are separated in quadrants labeled as follows: FP, false positive; TP, true positive; TN, true negative; FN, 
false negative. (B) Flow cytometric analyses of A-Red 0.8 µm beads incubated with PBMC spiked with different numbers of Sp2/0-MOv18 cells pre-labeled with  
an anti-CD45 antibody. Actual dilutions are indicated above each dot plot. The actual dilution was calculated by dividing the number of live Far-red positive  
events (antigen specific cells) by the number of live Far-red negative events (PBMC). Numbers in each quadrant indicate the absolute number of cells detected.  
(c) Calculation of Actual positive events and Actual true events from data obtained with “spiking” of PBMCs. Actual positive events and Actual true events for each 
frequency tested in B were calculated using the formulas on the left. (D) FRα+ beads of different sizes recognize Sp2/0-MOv18 B cells found at different frequencies 
in PBMCs. Actual positive events out of all bead-bound events were analyzed and demonstrate correlation between cell frequency and percentage of Actual positive 
events. A-Red 0.8 µm beads (left); SA-Blue 1.1 µm beads (middle), and LumAvidin 5.6 µm beads (right). Top panels: LC-LC biotin coupling; bottom panels: PEG12 
biotin coupling.
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were incubated with PBMC (1  µl beads/106 PBMC, Table S1 
in Supplementary Material) in the presence of serially diluted 
(1:50, 1:500, 1:5,000) Sp2/0-MOv18 cells pre-labeled with an 
anti-CD45 antibody. The actual dilution was calculated post 
acquisition (Figure 6B). Actual positive events were defined as 
anti-FRα antibody-expressing B cells among all bead-bound 
cells and used to evaluate potential specific selection of real 
antigen-specific cells. The Actual true events were defined 
as antigen-specific B  cells bound to beads among all possible 
antibody-specific Sp2/0+ events and used to estimate the selec-
tion of antigen-binding cells compared to all specific cells in a 
sample. We observed that FRα+ beads were able to identify 49% 
actual positive events (B cells) when the specific B cell frequency 
was ~1:50. The proportion of actual positive events (anti-FRα 
antibody-expressing B cells) was lower when the specific B cell 
frequencies in the PBMC pool were reduced (Figures  6B,C). 
The actual true events (B cells bound to beads among all pos-
sible antibody-expressing Sp2/0+ events) ranged between 9.4 
and 18% (Figures 6B,C). Beads of different types and diameter 
sizes varied in ability to detect Actual positive events, and the 
proportion of Actual positive events (among all bead-bound 
cells) decreased when the frequencies of FRα+/Sp2/0+ B cells 
were lower among PBMCs. Between 5 and 75% of antibody-
expressing B  cells recognized by beads were antigen-specific 
when B cells were found in high frequencies (≥1:100) in human 
blood. SA-Blue 1.1 µm LC-LC biotin beads detected the highest 
proportion (75%) when B cells were found at a frequency of 1:43 
(Figure 6D; Table S3 in Supplementary Material).
To confirm selection of antibody-expressing cells by spe-
cific antibody, PBMC spiking showed that FRα-coated beads 
were more likely than HER2-coated beads to be recognized 
by FRα-specific Sp2/0-MOv18 cells (Figure  7A; Figure S1 
in Supplementary Material). Anti-SF25 antibody-expressing 
Sp2/0 cells were also less likely to be detected by FRα-coated 
beads in PBMC samples (Figure 7A). Similarly, HER2-coated 
beads were more likely to bind anti-HER2 (trastuzumab)-
expressing Expi293F cells compared with anti-CSPG4 control 
antibody-expressing Expi293F cells. HER2-coated beads were 
also more likely to bind anti-HER2 (trastuzumab)-expressing 
Expi293F cells compared with FRα-coated beads, which showed 
low binding to anti-HER2 (trastuzumab)-expressing Expi293F 
cells (Figure  7B). Human Ig expression on the surface of 
Expi293F cells is shown in Figure S1 in Supplementary Material. 
Together, these data suggest that antibody-expressing cells in 
PBMC preparations are able to recognize beads conjugated to 
their specific antigens.
To interrogate this approach in the human setting, we eva-
luated whether fluorescent beads conjugated to melanoma cell 
surface antigens were able to identify antigen-reactive B cells. 
We prepared fluorescent beads coated with antigens extracted 
from human melanoma SK-MEL-28 cells, which natively express 
the tumor-associated antigen chondroitin sulfate proteoglycan 4 
(CSPG4). Melanoma antigen-coated beads were recognized by 
an anti-CSPG4 antibody but not by MOv18 antibody specific 
for the antigen FRα not expressed by SK-MEL-28 cells (Figure 
S2 in Supplementary Material), suggesting that antigen-reactive 
antibodies can specifically recognize antigen bound on these 
beads. We then screened for antigen-reactive antibodies from 
human B cells. PBMCs from patients with melanoma incubated 
with melanoma antigen-coated beads were screened to identify 
mature CD19/CD22+ B cells recognizing antigen-coated beads. 
Single bead-bound B  cells were isolated by single cell sorting 
Ig heavy and light chain sequences were amplified, sequenced, 
and antibodies were cloned (Figures  8A,B). An antibody 
derived from a single bead-bound B cell could recognize mela-
noma antigen-coated fluorescent beads compared with second-
ary only or a non-specific antibody control. The B cell-derived 
clone showed binding comparable to that of a monoclonal 
antibody specific for the melanoma-associated antigen CSPG4 
(Figure 8C).
Taken together, these findings suggest that antigen-reactive 
B cells in human blood could be recognized by antigen-conjugated 
fluorescent beads and could be sorted by flow cytometry for the 
expression of monoclonal antibodies.
DiscUssiOn
In this report, we present the development of a fluorescent bead 
method for the selection of single antigen-reactive B cell clones 
and the production of the cloned antigen-specific antibodies for 
downstream testing. The workflow comprises: (a) conjugation of 
fluorescent microspheres with a recombinant antigen of inter-
est; (b) identification of fluorescently labeled single antibody-
expressing B  cells by flow cytometry using antigen-conjugated 
beads; (c) flow cytometric sorting of bead-bound single cells 
directly into lysis buffer; (d) single cell retrotranscription and 
sequencing of matched heavy and light chain antibody variable 
regions; (e) cloning and expression using a vector containing 
human constant region cassettes; (f) confirmation of antigen 
reactivity of the produced full-length antibody. We designed this 
process to allow the identification of antigen-specific antibody-
expressing B cells without the requirement of prior ex vivo growth 
or secondary screening of B cells, and we aimed to conduct the 
workflow from clone identification to antibody production and 
characterization in a timeframe of approximately 23 days.
To design this protocol, we employed a model system featur-
ing human recombinant Folate Receptor alpha (FRα) as the target 
antigen, a B cell line expressing both the soluble and the membrane-
bound forms of MOv18 IgG1, a human/mouse chimeric antibody 
specific for FRα. We showed that fluorescent microspheres can be 
coupled with the recombinant antigen via biotin–streptavidin/
avidin bridging, and that immobilized antigens could be readily 
detected by antigen-specific monoclonal antibodies. Recognition 
of the epitope on FRα by the test antibody MOv18 is thought 
to be dependent on the native folding of the target antigen. 
Here, we demonstrated that it is possible to use antigen-coupled 
fluorescent beads of different sizes to identify and isolate single 
B cells expressing cell surface-expressed antibodies that recognize 
this conformational epitope. Antigen-antibody recognition could 
be improved by evaluating beads with different characteristics 
and diameters, while varying the lengths of the avidin coupling 
agents did not significantly influence antibody-expressing cell 
recognition by the beads. The latter observation also suggested 
that engagement of the antigen to the bead surface via different 
FigUre 7 | Detection of antibody-expressing or non-specific control antibody-expressing cells in peripheral blood mononuclear cells (PBMC) samples using 
fluorescent beads conjugated to recombinant antigens. (a) Flow cytometric dot plots of human PBMC incubated with FRα-coated A-Red 0.8 µm beads (top and 
middle) or with recombinant HER2-coated beads (bottom), spiked with different numbers of either Sp2/0-MOv18 cells (top and bottom), or non-specific SF25 
control monoclonal antibody-expressing Sp2/0 cells (middle), pre-labeled with Far-red cell tracking dye. Actual dilutions (calculated post acquisition) are indicated 
above each dot plot. The actual dilution was calculated by dividing the number of live Far-red positive events (antigen specific cells) by the number of live Far-red 
negative events (PBMC). Numbers in each quadrant indicate the absolute number of bead-bound cells detected. (B) Flow cytometric analyses of human PBMC 
incubated with A-Red 0.8 µm beads coated with human recombinant HER2 (top and middle) or with FRα (bottom), and spiked with different numbers of Expi293F 
cells expressing an anti-HER2 antibody (trastuzumab, top and bottom) or non-specific monoclonal antibody control (anti-CSPG4, middle). Expi293F cells were 
pre-labeled with Far-red cell tracking dye. Numbers in each quadrant indicate the absolute number of cells detected by antigen-coated beads.
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FigUre 8 | Selection of antibody-expressing B cells in peripheral blood mononuclear cells (PBMC) samples from patients with melanoma. (a) Representative flow 
cytometric dot plots of cell sorting gating strategy to select melanoma patient B cells recognizing melanoma cell line surface antigen (Ag)-coated fluorescent beads. 
Viable (live/dead dye) human CD45+ PBMC incubated with antigen-coated beads were identified (left) and B cells (CD19/CD22+ -FITC) recognizing antigen-coated 
beads (APC) were selected for single cell sorting (right). (B) Agarose gels of Ig heavy (left) and light (right) chain DNA fragments amplified through nested PCR. Each 
gel lane represents PCR products derived from a single B cell. Fragments of the expected sizes (~650 bp for the heavy chain, ~500 bp for the light chain fragments) 
were extracted and sequenced. Red boxes indicate matching Ig heavy and light chain DNA fragments originating from the same single B cell. (c) Flow cytometric 
dot plots depicting binding of two single B cell-derived monoclonal antibody clones (MM_Ib, MM_IV) to melanoma cell antigen-coated fluorescent beads  
(SK-MEL-28 melanoma cells). The bead-selected clone (MM_IV) bound to antigen-coated beads while the non-specific one (MM_Ib) did not show reactivity. 
Background binding was detected with secondary antibody alone, while beads were recognized by the positive control anti-CSPG4 antibody.
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biotins did not mask epitope recognition by specific antibody 
either in solution or when the antibody was expressed on the 
surface of a B cell.
A key feature of this streptavidin–biotin bead-based approach 
is that, in principle, it may enable the coupling of virtually any 
known native or recombinant antigen to fluorescent beads 
and facilitate the detection of B  cells reactive to this antigen. 
Our strategy may offer different features compared with those 
of other detection methods. For instance, antibodies used for 
detection of BCR on B cells may also interact not only with BCRs 
but also with Fc receptors on human B cells (30). Tetramer tech-
nologies may be applicable to the selection of antigen-specific 
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B cells, but fluorophores have been known to be released from 
antigen complexes and to bind non-specifically to immune cells, 
yielding false positive events (31). Our protocol is also specifi-
cally designed to avoid the requirement for B cell culture and 
ex vivo expansion or for antibody selection from culture super-
natants prior to sub-cloning, limiting dilution and isolation of 
antigen-specific B  cell clones. As well as being laborious and 
lengthy, these steps may also be limited by specific expansion 
of distinct B  cell populations not always representative of the 
original B cell repertoire, and which could suffer from potential 
loss of the antigen-specific clone during the cell ex vivo culture 
processes (17).
Following flow sorting of single cells directly into lysis buffer, 
we confirmed that it is possible to extract matched H and L chain 
variable region sequences from single antibody-expressing cells 
selected by specific antigen-coated beads. Employing the FRα-
MOv18 Sp2/0 B cell model, we confirmed that B cell selection 
by FRα+ fluorescent beads allowed the identification of the 
matched variable regions and permitted the cloning and produc-
tion of the corresponding monoclonal antibody from a single 
cell. This was greatly expedited with the use of a single vector 
Expi293F™ cell line-based expression system, which permitted 
antibody production within a few days (25, 26). While the vec-
tor used in this study contained the constant regions of human 
IgG1, in principle, this platform could be used for engineering 
of B  cell-derived antibodies with constant regions of any iso-
type or species desired, potentially facilitating a wide range of 
downstream applications for this technology. Importantly, we 
showed that cloned and expressed full-length antibody with 
variable regions extracted from a single B cell could recognize 
native cell surface-expressed human FRα. The specificity of an 
identified antibody could ultimately be confirmed only by the 
expression of the antibody and subsequent testing against the 
natively expressed antigen. Previous published studies report 
the number of detected B  cells and the antigenic reactivity of 
antibodies secreted in supernatants of ex vivo B  cell cultures 
without cloning, production, or testing of the derived antibody 
clones (16, 32). A similar B cell identification process to the one 
reported in our study described the frequency of antigen-specific 
B cells detected using a modified bead-based method (31). With 
this tool, it was possible to monitor the frequencies of anti-HLA, 
anti-tetanus toxin-, and anti-EBNA1-committed B cells in dif-
ferent individuals. However, antibodies from selected B  cells 
are often not cloned and expressed subsequently in order to 
analyze their ability to recognize natively expressed cognate 
antigens. Our data confirming antibody sequencing, cloning, 
expression, and antigen recognition provide an early proof of 
principle that functional Ig sequences could be recovered with 
this methodology.
We ascertained that binding of FRα-coated fluorescent 
beads can specifically single out antibody-expressing B  cells. 
We found that FRα-coated beads bound up to 71% of possible 
Sp2/0-MOv18 IgG cells. However, alongside enhanced recogni-
tion of possible antigen-reactive B cells, FRα-coated beads also 
bound to 6–9% of non-specific Sp2/0 B  cells. Furthermore, a 
proportion (~1%) of human circulating B  cells could bind 
to FRα-coated beads in most likely a non-specific manner. 
Together, these suggest that background non-specific binding 
of beads to cells may be a limitation of this methodology. We 
employed two approaches to evaluate whether antigen-coupled 
beads could detect antigen-reactive antibody-expressing cells in 
PBMC samples.
Our first approach was to “spike” human PBMC with Sp2/0-
MOv18 B cells at different frequencies. We demonstrated that 
FRα+ fluorescent beads could identify antibody-expressing cells 
among PBMC populations when these antigen-reactive cells 
were present at higher frequencies in human blood. We also 
found that different bead types had different specific recogni-
tion and background recognition profiles. The proportion of 
actual positive B  cells among all bead-bound cells decreased 
with lower frequencies of FRα+/Sp2/0+ B cells among PBMCs. 
When B cells were found in high frequencies (≥1:100) in human 
blood, the proportion of Actual positive events, the specific 
B cells recognized by the beads, ranged from 5 to 75% of the total 
bound cells, with the SA-Blue 1.1 µm LC-LC biotin beads able 
to detect the highest proportion (75%). Although fluorescent 
activated cell sorting could enable separating a single cell from 
a heterogeneous population, the detection of cell populations 
with a low frequency remains challenging and presents a tech-
nical limitation with different protocols (33, 34). Consistent 
with previous studies, here, we observed great variability in the 
acquired numbers of cells when analyzing samples with very low 
antigen-specific B cell frequencies. This implies that only active 
and high frequency humoral responses may be readily studied 
in the present context, while the detection of low frequency 
B  cells represents an inherent limitation of this methodology 
and requires further optimization. As a next step, we asked 
whether using this protocol, fluorescent beads coated with mela-
noma cell line antigens may be able to identify antigen-reactive 
B cells in individuals suffering of malignant melanoma. Using 
melanoma cell line surface antigen-coated fluorescent beads, we 
expressed a monoclonal antibody that bound to melanoma cell 
line protein-coated beads. This suggested that antigen-reactive 
B  cells in human blood may be singled out using fluorescent 
beads.
The selection of single antigen-specific B cells and the iden-
tification of their expressed antibodies is critical to gaining a 
deeper understanding of the nature and functions of active 
human humoral immune responses. Identification of B  cells, 
as well as cloning and production of their heavy and light 
chain matched antigen-specific monoclonal antibodies thus 
remain highly desirable in immunology research and antibody 
discovery. Consequently, discovery of antigen-specific B  cell 
clones forms the focus of numerous high- and low-throughput 
approaches (12–14). Our bead-based protocol may provide 
an alternative, readily applicable means for exploring human 
B  cells by facilitating the study of single B  cell-derived anti-
bodies and their functional profiles. Since the frequency of 
antigen-specific B cells in the human circulation remains ≤1% 
of the total B cell populations (35), increasing the probability 
for more specific selection of such low-frequency B  cells 
remains a major challenge with this and many other available 
technologies. Future efforts may help improve specific selection 
by incorporating additional selection markers such as beads 
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of multiple fluorophores (31), or B  cell activation markers 
to single out BCR-activated cells more likely to be matured 
antibody-expressing clones (36, 37). An alternative strategy 
may entail an additional imaging tool to verify selection of 
single antigen-reactive B cells subsequent to cell sorting (38). 
Furthermore, adjusting the cloning process to identify antibod-
ies of different subclasses or specificities or from specific B cell 
subsets could improve the chance of detecting clones and clonal 
families in certain diseases, in which immunological conditions 
may promote specific antibody profiles (39–42). Individually or 
combined, such approaches may help increase the chances of 
clonal selection.
In summary, we describe the establishment of a methodo-
logy to identify single antibody-expressing cells and to produce 
and test their sequenced recombinant antibodies in a workflow 
that may be readily applicable in any basic and translational 
immunology laboratory setting. This single cell-to-functional 
antibody strategy may open the way for new opportunities to 
analyze B cells and their antibody profiles at the single cell level 
and may be potentially applied to help unravel diverse humoral 
immune repertoires in blood and tissues and in different health 
and disease conditions.
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